Dr. Amengual is an Assistant Professor of Medicine and Developmental Therapeutics. Her research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, she aims to directly translate observations and concepts developed in the laboratory to patient care.
|Lymphoma||[ CLOSED ] Study for patients with newly diagnosed Mantle Cell Lymphoma using study drug (BTK Inhibitor)|
|Lymphoma||[ CLOSED ] Study of Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Subjects with Hodgkin Lymphoma|
|Cancer||Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer|
|Lymphoma||[ CLOSED ] Study of Nivolumab Plus Standard Chemotherapy in Comparison to Brentuximab Vedotin Plus Standard Chemotherapy for Advanced Hodgkin Lymphoma|
|Lymphoma||Study of Tazemetostat or Placebo with Lenalidomide plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma|
|Lymphoma||Study of Lenalidomide in Combination with Chemotherapy in Patients with HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)|